Correction: A novel biocompatible,simvastatin-loaded,bone-targeting lipid nanocarrier for treating osteoporosis more effectively

Correction for ‘A novel biocompatible, simvastatin-loaded, bone-targeting lipid nanocarrier for treating osteoporosis more effectively’ by Shan Tao et al., RSC Adv., 2020, 10, 20445–20459, DOI: 10.1039/D0RA00685H.

The authors regret that incorrect versions of Fig. 7, ​,99 and ​and1010 were included in the original article. The correct versions of Fig. 7, ​,99 and ​and1010 are presented below.Open in a separate windowFig. 7Histological analysis of organs from all experimental groups. H&E staining of heart, liver, spleen, lung, kidney, indicating the carrier has good biocompatibility. Scale bar = 50 μm.Open in a separate windowFig. 9Alkaline phosphatase (ALP) activity (arrows) and tartrate-resistant acid phosphatase (TRAP) assay results (arrowheads) of bone tissue sections. Scale bar = 50 μm. The ALP activity is much more high in SIM/LNPs and SIM/ASP₆-LNPs groups, while the TRAP activity is the opposite.Open in a separate windowFig. 10Histological assessment of bone formation in all experimental groups. (A) HE staining of femur bone. Scale bar = 50 μm. Histology of bone in the all experimental groups shows all ovariectomized groups had a higher amount of adipose tissue than Sham group. The trabecular bone is much more prominent in SIM/LNPs and SIM/ASP₆-LNPs groups. (B) Immunohistochemical staining for BMP-2 in typical newly-formed bone tissue (red arrows) and immunohistochemical staining for the osteogenic markers osteopontin (OPN, arrows) and osteocalcin (OCN, arrowheads). Scale bar = 50 μm. The BMP-2, OPN, OCN are much more prominent in SIM/LNPs and SIM/ASP₆-LNPs groups.The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.